• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.用针对NY-ESO-1的自体CD4+ T细胞治疗转移性黑色素瘤。
N Engl J Med. 2008 Jun 19;358(25):2698-703. doi: 10.1056/NEJMoa0800251.
2
Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient.CHP-NY-ESO-1疫苗接种诱导黑色素瘤患者针对NY-ESO-1的免疫反应及免疫调节
Cancer Immunol Immunother. 2008 Oct;57(10):1429-37. doi: 10.1007/s00262-008-0478-5. Epub 2008 Mar 1.
3
Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients.在 4 名晚期黑色素瘤患者接受伊匹单抗治疗后，肿瘤反应性细胞毒性 CD4+ T 细胞反应增强。
Cancer Immunol Res. 2013 Oct;1(4):235-44. doi: 10.1158/2326-6066.CIR-13-0068.
4
One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.一种源自NY-ESO-1的表位，它能与多种HLA-DR和HLA-DP4分子发生混杂结合，并刺激来自表达NY-ESO-1的黑色素瘤患者的自体CD4+ T细胞。
J Immunol. 2005 Feb 1;174(3):1751-9. doi: 10.4049/jimmunol.174.3.1751.
5
Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.NY-ESO-1 蛋白、Poly-ICLC 和 Montanide 联合疫苗可提高高危黑色素瘤患者的体液和细胞免疫应答。
Cancer Immunol Res. 2020 Jan;8(1):70-80. doi: 10.1158/2326-6066.CIR-19-0545. Epub 2019 Nov 7.
6
The Tumor Antigen NY-ESO-1 Mediates Direct Recognition of Melanoma Cells by CD4+ T Cells after Intercellular Antigen Transfer.肿瘤抗原NY-ESO-1在细胞间抗原转移后介导CD4 + T细胞对黑色素瘤细胞的直接识别。
J Immunol. 2016 Jan 1;196(1):64-71. doi: 10.4049/jimmunol.1402664. Epub 2015 Nov 25.
7
Circulating CD4+ T cells that produce IL4 or IL17 when stimulated by melan-A but not by NY-ESO-1 have negative impacts on survival of patients with stage IV melanoma.当被黑素瘤抗原-A（melan-A）刺激时产生白细胞介素-4（IL4）或白细胞介素-17（IL17）的循环 CD4+T 细胞对 IV 期黑色素瘤患者的生存有负面影响。
Clin Cancer Res. 2014 Aug 15;20(16):4390-9. doi: 10.1158/1078-0432.CCR-14-1015. Epub 2014 Jun 17.
8
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.CTLA-4阻断增强转移性黑色素瘤患者中具有临床获益的多功能NY-ESO-1特异性T细胞反应。
Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20410-5. doi: 10.1073/pnas.0810114105. Epub 2008 Dec 12.
9
A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.一项使用经NY-ESO-1反应性T细胞受体基因工程改造的淋巴细胞的试点试验：长期随访及与反应的相关性。
Clin Cancer Res. 2015 Mar 1;21(5):1019-27. doi: 10.1158/1078-0432.CCR-14-2708. Epub 2014 Dec 23.
10
Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011.由HLA-DQ B1 03011递呈的、可被CD4+ T细胞识别的新型NY-ESO-1表位的鉴定。
Int J Cancer. 2006 Feb 1;118(3):668-74. doi: 10.1002/ijc.21391.

引用本文的文献

1
Targeting the roots of myeloid malignancies with T cell receptors.利用T细胞受体靶向髓系恶性肿瘤的根源。
Nat Rev Cancer. 2025 Aug 21. doi: 10.1038/s41568-025-00857-0.
2
Engineered CD4 TCR T cells with conserved high-affinity TCRs targeting NY-ESO-1 for advanced cellular therapies in cancer.工程化的CD4 TCR T细胞，具有针对NY-ESO-1的保守高亲和力TCR，用于癌症的先进细胞疗法。
Sci Adv. 2025 Jun 27;11(26):eadu5754. doi: 10.1126/sciadv.adu5754.
3
Rapid enrichment of progenitor exhausted neoantigen-specific CD8 T cells from peripheral blood.从外周血中快速富集祖细胞耗竭的新抗原特异性CD8 T细胞。
bioRxiv. 2025 May 15:2025.05.11.653315. doi: 10.1101/2025.05.11.653315.
4
Adoptive T Cell Therapy Targeting MAGE-A4.靶向黑素瘤相关抗原A4的过继性T细胞疗法
Cancers (Basel). 2025 Jan 26;17(3):413. doi: 10.3390/cancers17030413.
5
Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer.人 HLA Ⅱ类分子限制性新抗原肽负载树突状细胞疫苗治疗乳腺癌的回顾性分析
Cancers (Basel). 2024 Dec 17;16(24):4204. doi: 10.3390/cancers16244204.
6
Overcoming Resistance Mechanisms to Melanoma Immunotherapy.克服黑色素瘤免疫疗法的耐药机制
Am J Clin Dermatol. 2025 Jan;26(1):77-96. doi: 10.1007/s40257-024-00907-7. Epub 2024 Dec 5.
7
TIL Therapy in Lung Cancer: Current Progress and Perspectives.肺癌中的肿瘤浸润淋巴细胞疗法：当前进展与展望
Adv Sci (Weinh). 2024 Dec;11(46):e2409356. doi: 10.1002/advs.202409356. Epub 2024 Oct 18.
8
NY-ESO-1 antigen: A promising frontier in cancer immunotherapy.NY-ESO-1 抗原：癌症免疫治疗的一个有前途的前沿领域。
Clin Transl Med. 2024 Sep;14(9):e70020. doi: 10.1002/ctm2.70020.
9
CD4 T cells with convergent TCR recombination reprogram stroma and halt tumor progression in adoptive therapy.具有趋同 TCR 重组的 CD4 T 细胞重编程基质并在过继治疗中阻止肿瘤进展。
Sci Immunol. 2024 Sep 13;9(99):eadp6529. doi: 10.1126/sciimmunol.adp6529.
10
Diagnostic Approach to IgG4-Related Retroperitoneal Fibrosis After Colorectal Cancer Surgery in a Patient With Normal IgG4 Levels: A Case Report.IgG4水平正常的结直肠癌患者术后IgG4相关性腹膜后纤维化的诊断方法：一例报告
Cureus. 2024 Jul 5;16(7):e63894. doi: 10.7759/cureus.63894. eCollection 2024 Jul.

本文引用的文献

1
Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.接种具有HLA I/II类特异性的NY-ESO-1肽可在卵巢癌中诱导整合的体液和T细胞反应。
Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12837-42. doi: 10.1073/pnas.0703342104. Epub 2007 Jul 25.
2
Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.采用抗原特异性CD8 + T细胞的过继性T细胞疗法治疗转移性黑色素瘤患者的I期研究。
J Clin Oncol. 2006 Nov 1;24(31):5060-9. doi: 10.1200/JCO.2006.07.1100.
3
Adoptive immunotherapy for cancer: building on success.癌症的过继性免疫疗法：基于成功经验。
Nat Rev Immunol. 2006 May;6(5):383-93. doi: 10.1038/nri1842.
4
IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response.白细胞介素-21影响抗原特异性CD8 T细胞反应的频率、表型和亲和力。
J Immunol. 2005 Aug 15;175(4):2261-9. doi: 10.4049/jimmunol.175.4.2261.
5
Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen.使用来自NY-ESO-1抗原的表位对患有转移性黑色素瘤的HLA-A*0201和/或HLA-DPbeta1*04患者进行免疫治疗。
J Immunother. 2004 Nov-Dec;27(6):472-7. doi: 10.1097/00002371-200411000-00007.
6
Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes.在树突状细胞成熟后转染编码肿瘤抗原的RNA可导致抗原的持续呈递以及高亲和力肿瘤反应性细胞毒性T淋巴细胞的产生。
Mol Ther. 2004 May;9(5):757-64. doi: 10.1016/j.ymthe.2004.02.011.
7
Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses.癌症患者中针对NY-ESO-1的天然CD4+ T细胞反应调查：与抗体反应的相关性
Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8862-7. doi: 10.1073/pnas.1133324100. Epub 2003 Jul 9.
8
Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells.体内诱导肿瘤细胞凋亡可增加肿瘤抗原的交叉呈递，从而激活而非诱导宿主肿瘤特异性CD8 T细胞产生交叉耐受。
J Immunol. 2003 May 15;170(10):4905-13. doi: 10.4049/jimmunol.170.10.4905.
9
Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.采用抗原特异性CD8 + T细胞克隆的过继性T细胞疗法治疗转移性黑色素瘤患者：转移T细胞的体内持久性、迁移及抗肿瘤作用
Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16168-73. doi: 10.1073/pnas.242600099. Epub 2002 Nov 11.
10
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.抗肿瘤淋巴细胞克隆性再增殖后患者的癌症消退与自身免疫
Science. 2002 Oct 25;298(5594):850-4. doi: 10.1126/science.1076514. Epub 2002 Sep 19.

用针对NY-ESO-1的自体CD4+ T细胞治疗转移性黑色素瘤。

Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.

作者信息

Hunder Naomi N, Wallen Herschel, Cao Jianhong, Hendricks Deborah W, Reilly John Z, Rodmyre Rebecca, Jungbluth Achim, Gnjatic Sacha, Thompson John A, Yee Cassian

机构信息

Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.

出版信息

N Engl J Med. 2008 Jun 19;358(25):2698-703. doi: 10.1056/NEJMoa0800251.

DOI:10.1056/NEJMoa0800251
PMID:18565862
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3277288/
Abstract

We developed an in vitro method for isolating and expanding autologous CD4+ T-cell clones with specificity for the melanoma-associated antigen NY-ESO-1. We infused these cells into a patient with refractory metastatic melanoma who had not undergone any previous conditioning or cytokine treatment. We show that the transferred CD4+ T cells mediated a durable clinical remission and led to endogenous responses against melanoma antigens other than NY-ESO-1.

摘要

我们开发了一种体外方法，用于分离和扩增对黑色素瘤相关抗原NY-ESO-1具有特异性的自体CD4+ T细胞克隆。我们将这些细胞注入一名患有难治性转移性黑色素瘤的患者体内，该患者此前未接受过任何预处理或细胞因子治疗。我们发现，转移的CD4+ T细胞介导了持久的临床缓解，并引发了针对NY-ESO-1以外的黑色素瘤抗原的内源性反应。